Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002274 · ClinicalTrials.gov registry record · NA
A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine
A NA study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- NA
- Development phase
NCT00002274 is a NA study that has completed, run by Bristol-Myers Squibb.
The verdict
NCT00002274, a NA study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The objective of this open-label study regimen is to make didanosine (ddI) available to patients with AIDS who are clinically deteriorating on zidovudine (AZT) and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.
Interventions
- DRUG Didanosine
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002274
The ClinicalTrials.gov registry entry for NCT00002274 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Didanosine is the first listed.
NCT00002274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002274 about?
NCT00002274 is a clinical study titled "A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine". The objective of this open-label study regimen is to make didanosine (ddI) available to patients with AIDS who are clinically deteriorating on zidovudine (AZT) and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.
What is the current status of trial NCT00002274?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002274?
The interventions under investigation include: Didanosine (DRUG).
Who is sponsoring clinical trial NCT00002274?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.